BIM
RNAC icon

BlackRock Investment Management’s Cartesian Therapeutics RNAC Stock Holding History

BlackRock Investment Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$97K Buy
188
+97
+107% +$56.7K ﹤0.01% 3274
2016
Q3 		$39K Buy
+91
New +$35.6K ﹤0.01% 3305

Other funds holding RNAC

PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
SRF
Silver Rock Financial Los Angeles, California $49.7M AUM 17.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock Investment Management's RNAC Position: Q4 2016 in Review

BlackRock Investment Management increased its Cartesian Therapeutics (RNAC) stake by 107% in Q4 2016, buying an estimated $56.7K and bringing the position to 188 shares worth $97K. The position accounts for ﹤0.01% of the portfolio, ranked #3274.

BlackRock Investment Management first reported a position in RNAC in Q3 2016 and has held it in 2 quarters since. 43 funds tracked by Wall St. Rank hold RNAC as of Q4 2016.

  • BlackRock Investment Management held 188 shares of Cartesian Therapeutics worth $97K as of Q4 2016.
  • BlackRock Investment Management bought 97 Cartesian Therapeutics shares in Q4 2016, an estimated $56.7K.
  • Cartesian Therapeutics made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #3274 holding.
  • BlackRock Investment Management first reported a position in Cartesian Therapeutics in Q3 2016 and has held it in 2 quarters since.
  • 43 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.